OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, announced that its Executive Chairman, Gabriele Cerrone, has increased his stake in the company. Through Panetta Partners , an entity in which Cerrone has a beneficial interest, 50,000 ordinary shares were purchased on NASDAQ at $1.05 per share. This acquisition brings Cerrone's total shareholding to 9,721,570 shares, representing 28.73% of the company's issued share capital. OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), targeting multi-billion-dollar markets.
OKYO Pharma (NASDAQ: OKYO), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie oculari innovative, ha annunciato che il suo Presidente Esecutivo, Gabriele Cerrone, ha aumentato la sua partecipazione nella società. Attraverso Panetta Partners, un'entità in cui Cerrone ha un interesse economico, sono state acquistate 50.000 azioni ordinarie su NASDAQ a $1,05 per azione. Questa acquisizione porta la partecipazione totale di Cerrone a 9.721.570 azioni, rappresentando 28,73% del capitale sociale emesso dell'azienda. OKYO Pharma si specializza nei trattamenti per la malattia infiammatoria dell'occhio secco (DED) e il dolore corneale neuropatico (NCP), mirando a mercati da miliardi di dollari.
OKYO Pharma (NASDAQ: OKYO), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias oculares innovadoras, anunció que su Presidente Ejecutivo, Gabriele Cerrone, ha aumentado su participación en la compañía. A través de Panetta Partners, una entidad en la que Cerrone tiene un interés económico, se adquirieron 50,000 acciones ordinarias en NASDAQ a $1.05 por acción. Esta adquisición eleva el total de acciones de Cerrone a 9,721,570 acciones, lo que representa 28.73% del capital social emitido de la compañía. OKYO Pharma se especializa en tratamientos para la enfermedad del ojo seco inflamatorio (DED) y dolor corneal neuropático (NCP), apuntando a mercados de miles de millones de dólares.
OKYO Pharma (NASDAQ: OKYO)는 혁신적인 안과 치료 개발에 중점을 둔 임상 단계의 생명공학 회사로, 실행 의장인 가브리엘레 체론이 회사의 지분을 늘렸다고 발표했습니다. 체론이 이익을 얻는 Panetta Partners를 통해 50,000주의 보통주가 NASDAQ에서 1.05달러에 주당 구입되었습니다. 이 인수로 체론의 총 보유 지분은 9,721,570주로 증가하며, 이는 회사의 발행 주식 자본의 28.73%를 차지합니다. OKYO Pharma는 염증성 건조안 질환(DED) 및 신경성 각막 통증(NCP) 치료에 전문화되어 있으며, 수십억 달러 규모의 시장을 목표로 하고 있습니다.
OKYO Pharma (NASDAQ: OKYO), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies oculaires innovantes, a annoncé que son Président Exécutif, Gabriele Cerrone, a augmenté sa participation dans l'entreprise. Par l'intermédiaire de Panetta Partners, une entité dans laquelle Cerrone a un intérêt économique, 50 000 actions ordinaires ont été achetées sur NASDAQ à 1,05 $ par action. Cette acquisition porte la participation totale de Cerrone à 9 721 570 actions, représentant 28,73 % du capital social émis de l'entreprise. OKYO Pharma se spécialise dans les traitements des maladies inflammatoires de l'œil sec (DED) et de la douleur cornéenne neuropathique (NCP), visant des marchés de plusieurs milliards de dollars.
OKYO Pharma (NASDAQ: OKYO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Augenheilverfahren konzentriert, gab bekannt, dass der Executive Chairman, Gabriele Cerrone, seinen Anteil am Unternehmen erhöht hat. Über Panetta Partners, eine Einheit, an der Cerrone ein wirtschaftliches Interesse hat, wurden 50.000 Stammaktien an der NASDAQ zum Preis von 1,05 $ pro Aktie erworben. Diese Akquisition erhöht Cerrones Gesamtanteil auf 9.721.570 Aktien, was 28,73 % des ausgegebenen Aktienkapitals des Unternehmens entspricht. OKYO Pharma spezialisiert sich auf die Behandlung von entzündlichem trockenem Auge (DED) und neuropathischen Hornhautschmerzen (NCP) und zielt auf Märkte im Wert von mehreren Milliarden Dollar ab.
- Executive Chairman's increased stake demonstrates confidence in the company
- Insider buying often signals positive outlook for the company's future
- OKYO Pharma targets multi-billion-dollar markets in ocular therapies
- High concentration of ownership (28.73%) by a single individual may raise governance concerns
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company’s ordinary shares on NASDAQ at a price of US
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
How many shares did OKYO Pharma's Chairman acquire on August 23, 2024?
What is the current ownership percentage of OKYO Pharma's Executive Chairman after the recent purchase?
What was the price per share for the recent OKYO stock purchase by the Chairman?
What are the main therapeutic areas OKYO Pharma (OKYO) focuses on?
